Posted by Michael Wonder on 25 Mar 2019
Mavenclad (cladribine tablets) approved as the first short-course oral treatment for relapsing remitting multiple sclerosis in Switzerland
25 March 2019 - Approval based on extensive clinical development program capturing more than 10,000 patient years of safety data and up to 10 years of follow-up in some patients.
Merck today announced that Mavenclad (cladribine tablets) has been approved for the treatment of highly active relapsing remitting multiple sclerosis* (RRMS) in Switzerland. Mavenclad is the first treatment for RRMS that provides the possibility of up to four years of disease control with a maximum of 20 days of oral treatment administered over two years.
“The Swissmedic approval of Mavenclad is great news for patients in Switzerland with highly active relapsing remitting MS,” said Luciano Rossetti, Head of Global Research & Development for the Biopharma business of Merck. “These patients have had limited treatment options and Mavenclad, now approved in 52 countries worldwide, represents an important new therapy with a novel mechanism as the first short-course oral treatment for relapsing remitting MS in Switzerland.”
